B
Bull
Bull · 25%ANVS
$2.39
Precio del escenario
$1.720
-0.085 (-4.97%)Al cierre
Loading chart…
- High
- 1.830
- Open
- 1.780
- VWAP
- 1.75
- Vol
- 504.51K
- Mkt Cap
- 67.03M
- Low
- 1.710
- Amount
- 884.58K
- EV/EBITDA, TTM
- 0.00
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
AI analysis of Annovis Bio Inc (ANVS)
sellAnnovis Bio Inc is not a good buy right now due to significant financial losses and low stock price. The current price is $1.72, with a year-to-date change of -52.88% and a negative net income of -17606382 USD in Q1 2026. The upcoming Phase 3 readout poses a risk, as a negative result could severely impact operations and stock value.
Métricas de valoración
The current forward P/E ratio for Annovis Bio Inc (ANVS) is 0.00, compared to its 5-year average forward P/E of -4.15.
Alphio AI Price Scenarios for ANVS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.505-27NASDAQ.COMAnnovis Bio Regains NYSE Compliance Ahead of Schedule
8.505-26seekingalphaAnnovis Bio Restores Compliance with NYSE Listing Standards
8.505-21NASDAQ.COMAnnovis Bio Inc. Prices Public Offering to Raise $15 Million
8.505-20seekingalphaAnnovis Bio's Stock Drops After $15M Offering Announcement
8.505-20NASDAQ.COMAnnovis Bio Announces Public Offering for Neurodegenerative Drug Development
ANVS FAQ — answered by Alphio AI
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Annovis Bio Inc is not a good buy right now due to significant financial losses and low stock price. The current price is $1.72, with a year-to-date change of -52.88% and a negative net income of -17606382 USD in Q1 2026. The upcoming Phase 3 readout poses a risk, as a negative result could severely impact operations and stock value.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.